Cerevel Therapeutics Inc... (CERE)
NASDAQ: CERE
· Real-Time Price · USD
44.96
0.33 (0.74%)
At close: Jul 31, 2024, 10:00 PM
Cerevel Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -266.51M | -238.89M | -199.04M | -306.8M | -387.5M | -351.51M | -317.76M | -279.88M | -242.65M | -225.33M | -199.46M | -176.44M | -149.91M |
Depreciation & Amortization | 5.85M | 421K | 212K | 30K | -100K | 4.9M | 4.7M | 4.41M | 3.79M | 2.73M | 1.71M | 776K | 365K |
Stock-Based Compensation | 77.75M | 69.41M | 54.57M | 47.17M | 42.81M | 38.78M | 34.89M | 31.33M | 26.36M | 23.94M | 18.11M | 15.45M | 13.69M |
Other Working Capital | 17.94M | 24.69M | 28.88M | 13.21M | 34.5M | 28.83M | 15.25M | 19.54M | 408K | 8.26M | 8.54M | 19.11M | 21.57M |
Other Non-Cash Items | 24.84M | 33.31M | -8.41M | 5.05M | -6.83M | -13.88M | -5.63M | -5.64M | -2.75M | 694K | 5.7M | -457K | 1.75M |
Deferred Income Tax | -230.52M | -230.52M | -202.57M | -94.07M | n/a | n/a | n/a | 1.71M | 3.46M | 3.88M | -4.82M | -1.85M | -12.02M |
Change in Working Capital | 21.55M | 23.96M | 22.88M | 8.48M | 30.7M | 28.06M | 24.89M | 25.79M | 2.01M | 15.54M | 11.25M | 18.71M | 21.36M |
Operating Cash Flow | -367.05M | -342.3M | -332.36M | -340.13M | -320.46M | -293.19M | -258.45M | -221.82M | -209.78M | -178.55M | -167.5M | -143.81M | -124.77M |
Capital Expenditures | -3.74M | -3.81M | -3.36M | -3.02M | -2.09M | -3.95M | -4.57M | -5.59M | -8.04M | -10.5M | -16.98M | -23.09M | -21M |
Cash Acquisitions | 33.59K | 38.58M | 38.45M | 38.89M | 38.96M | 413.96K | 387.68K | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -800.29M | -865.27M | -722.7M | -1.08B | -1.02B | -887.74M | -1.14B | -566.72M | -485.4M | -425.16M | n/a | n/a | n/a |
Sales Maturities Of Investments | 786.13M | 942.8M | 923.26M | 842.26M | 777.71M | 502.86M | 354.65M | 170.65M | 23.9M | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -33.59K | -38.58M | -38.45M | -38.89M | 26.47M | 64.98M | 64.58M | 64.96M | -461.5K | -425.16K | n/a | n/a | n/a |
Investing Cash Flow | -17.9M | 73.72M | 197.2M | -242.05M | -239.51M | -388.83M | -788.33M | -401.67M | -469.54M | -435.66M | -16.98M | -23.09M | -21M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | -75K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 551.66M | 548.62M | 42.38M | 619.82M | 622.02M | 623.19M | 623.38M | 432.31M | 425.46M | 423.6M | 841.36M | 476.06M | 441.58M |
Financial Cash Flow | 551.66M | 548.62M | 42.38M | 619.82M | 622.02M | 623.19M | 623.38M | 432.31M | 425.46M | 423.6M | 841.36M | 476.06M | 441.58M |
Net Cash Flow | 220.05M | 333.38M | -92.79M | 37.64M | 62.05M | -58.83M | -423.41M | -191.18M | -253.86M | -190.6M | 656.87M | 309.16M | 295.81M |
Free Cash Flow | -370.79M | -346.11M | -335.72M | -343.15M | -322.56M | -297.14M | -263.02M | -227.41M | -217.82M | -189.05M | -184.49M | -166.9M | -145.76M |